PLEASONTON, CALIF., NANJING, and SHANGHAI, July 29, 2021 - IASO Biotherapeutics (IASO Bio), a clinical-stage biopharmaceutical company advancing the development of novel cell therapies for cancer, today announced the clearance from China’s National Medical Products Administration (NMPA) of two Initial New Drug (IND) applications for CT120, the company’s in-house developed fully human CD19/CD22 dual-targeted chimeric antigen receptor (CAR)-T cell therapy for the treatment of CD19/CD22-positive relapsed/refractory B-cell non-Hodgkin's lymphoma (r/r B-NHL) and relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL).
a asgdasgasgasgd
PLEASANTON, CALIF., NANJING, CHINA, June 8, 2021 – IASO Biotherapeutics (IASO Bio), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and autoimmune diseases, and Innovent Biologics, Inc. (“Innovent”, HKEX: 01801) jointly announced to deliver an oral presentation on updated data from the Phase I study of CT103A in patients with relapsed/refractory multiple myeloma (R/R MM) at the European Hematology Association (EHA) Congress, June 9-17, 2021. The presentation will further demonstrate the safety, efficacy, and increased persistence of CT103A.
PLEASANTON, CALIF., NANJING, CHINA, June 3, 2021-—IASO Biotherapeutics (IASO Bio), and Innovent Biologics, Inc. (Innovent, HKEX: 01801), today jointly announced that the results of initial clinical studies on treatment of relapsed or refractory multiple myeloma (R/R MM）in subjects using fully human BCMA-targeting CAR (CT103A), an investigational chimeric antigen receptor (CAR) T-cell therapy co-developed by IASO Bio and Innovent (IASO Bio: CT103A, Innovent: IBI326) was published in “Blood”, a peer-reviewed medical journal specializing in hematology.
PLEASANTON, CALIF., NANJING, CHINA, May 21, 2021 - IASO Biotherapeutics announces today that its clinical trial application for the in-house developed CD19-CD22 fully human dual-targeted CAR T-cell therapy (CT120) for the treatment of its second indication, relapsed/refractory B-cell non-Hodgkin's lymphoma (B-NHL), has been accepted by National Medical Products Administration (NMPA) (Acceptance No.: CXSL2101088, CXSL2101089). This acceptance comes only one day after the acceptance of the drug’s first indication for the treatment of CD19/CD22 positive relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL). This success in clinical trial application further highlights the company’s speed of and strength in the development of innovative novel CAR-T therapies.
PLEASANTON, CALIF., NANJING, CHINA, May 21, 2021 - IASO Biotherapeutics announces today that its clinical trial application for the in-house developed CD19-CD22 fully human dual-targeted CAR T-cell therapy (CT120) for the treatment of its second indication, relapsed/refractory B-cell non-Hodgkin's lymphoma (B-NHL), has been accepted by National Medical Products Administration (NMPA) (Acceptance No.: CXSL2101088, CXSL2101089). This acceptance comes only one day after the acceptance of the drug’s first indication for the treatment of CD19/CD22 positive relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL). This success in clinical trial application further highlights the company’s speed of and strength in the development of innovative novel CAR-T therapies.
PLEASANTON, CALIF., NANJING, CHINA, May 19, 2021 - IASO Biotherapeutics (IASO Bio) today announced that the Center for Drug Evaluation of the China National Medical Products Administration (NMPA) has accepted (acceptance number CXSL2101070) the investigational new drug (IND) application for CT120, an investigational fully human CD19/CD22 dual-targeting chimeric antigen receptor (CAR)-T cell therapy independently developed by IASO Bio for treatment of relapsed/refractory B-acute lymphoblastic leukemia (B-ALL). CT120 is the second clinical stage CAR-T therapies developed by IASO Bio, which signifies the company’s solid step in the development of next-generation CAR-T therapies.
PLEASANTON, CALIF., NANJING, CHINA, February 22, 2021-- IASO Biotherapeutics (IASO Bio) and Innovent Biologics, Inc. (Innovent, HKEX: 01801), today jointly announced that the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has granted Breakthrough Therapy Designation (BTD) for CT103A, an investigational chimeric antigen receptor (CAR)-T cell therapy co-developed by IASO Bio and Innovent (IASO Bio: CT103A, Innovent: IBI326), for treatment of relapsed/refractory multiple myeloma. NMPA grants Breakthrough Therapy Designation to new medicines that are intended to treat serious conditions and where clinical evidence indicates that the drug may demonstrate substantial improvement over available therapy on a clinically significant endpoint. The BTD designation for CT103A is based on the results observed in ongoing Phase 1/2 study for the treatment of adults with relapsed or refractory multiple myeloma (RRMM) being conducted in China (ChiCTR1800018137).
2020 Nanjing International Life & Health Conference was successfully held in Nanjing International Expo Center during December 9 to 11. The conference was guided by Nanjing Municipal Government and hosted by Nanjing Jiangbei New Area. As one of the most significant sub-forum of the conference, the "Cell Therapy Summit Forum" organized by IASO BIO was successfully held on December 10. The forum has attracted a number of experts, scholars, industry pioneers and on-site audiences to attend and proved participants a lively exchange of forward looking ideas and the sharing of "opportunities & challenges faced by tumor immunotherapy".
IASO Bio, a clinical-stage company focused on developing and commercializing novel cellular immunotherapy to treat cancer, is pleasant to announce the appointment of Dr. Biao Zheng as Chief Scientific Officer (CSO), and the appointment of Dr. Wen Wang as Chief Medical Officer (CMO).
